Lakefront Biotherapeutics (GLPGF) Accumulated Expenses (2013 - 2018)

Lakefront Biotherapeutics (GLPGF) has reported Accumulated Expenses for 6 consecutive years, with $1.0 million the latest figure, recorded in Q3 2018.

• On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $1.0 million in Q3 2018; TTM through Sep 2018 was $1.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $1.4 million, up 99.14% from the prior year.
• Accumulated Expenses was $1.0 million for Q3 2018 at Lakefront Biotherapeutics, down from $1.0 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.0 billion in Q2 2018 and troughed at $537097.5 in Q4 2015.
• A 5-year average of $103.6 million and a median of $994836.4 in 2017 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 86.08% in 2014 and jumped 89413.83% in 2018, its largest moves.
• Over 5 years, Accumulated Expenses stood at $731152.6 in 2014, then slipped by 26.54% to $537097.5 in 2015, then rose by 24.44% to $668349.3 in 2016, then soared by 104.18% to $1.4 million in 2017, then declined by 26.1% to $1.0 million in 2018.
• The last three Accumulated Expenses figures came in at $1.0 million (Q3 2018), $1.0 billion (Q2 2018), and $1.2 million (Q1 2018), per Business Quant data.